血清miR-146a与miR-34a表达水平对ACS冠脉病变及预后评估价值

牛君义; 陈凤英; 狄祥龙; 陈敬严; 谢秀峰

doi:10.13201/j.issn.1001-1439.2020.09.008

血清miR-146a与miR-34a表达水平对ACS冠脉病变及预后评估价值

- 内蒙古医科大学附属医院急诊科(呼和浩特, 010050)
基金项目:
内蒙古医科大学科技百万工程(No:YKD2016KJBW007)

详细信息

通讯作者: 谢秀峰,E-mail:bbgqiyang1001@163.com

中图分类号: R541.4

收稿日期: 2020-06-08

Clinical value of serum levels of miR-146a and miR-34a to the severity and prognosis in patients with acute coronary syndrome

- Department of Emergency, Affiliated Hospital of Inner Mongolia Medical University, Huhhot, 010050, China

More Information

Corresponding author: XIE Xiufeng, E-mail: bbgqiyang1001@163.com

Received Date: 08 June 2020

摘要

摘要: 目的:探讨急性冠状动脉综合征(ACS)患者血清miR-146a、miR-34a表达水平及临床价值。方法:选取2018年2月-2019年7月在内蒙古医科大学附属医院行冠状动脉(冠脉)造影术的100例ACS患者为研究对象,同期选取100例体检人群为对照组。造影结果行Gensini评分,将ACS患者分为轻度组(47例)、中度组(34例)、重度组(19例)。采用实时荧光定量PCR法检测各组miR-146a、miR-34a表达水平。随访患者1年内主要不良心血管事件(MACE)发生情况。结果:ACS 3组患者血清miR-146a、miR-34a表达均高于对照组,差异有统计学意义(P<0.05);重度组miR-146a、miR-34a表达水平高于中度组与轻度组,并且中度组miR-146a、miR-34a表达水平高于轻度组,差异均有统计学意义(P<0.05)。随访1年,MACE亚组血清miR-146a、miR-34a表达水平高于非MACE亚组,差异有统计学意义(P<0.05)。结论:ACS患者血清miR-146a、miR-34a呈高表达,并与冠脉病变程度密切相关。
- 急性冠状动脉综合征 /
- miR-146a /
- miR-34a /
- 冠状动脉病变 /
- 主要不良心血管事件
Abstract: Objective:To explore the serum levels and clinical value of miR-146 a and miR-34 a in patients with acute coronary syndrome(ACS).Method:The 100 patients with ACS who underwent coronary angiography from February 2018 to July 2019 were collected to ACS group.And the 100 healthy volunteers during the same period were enrolled to control group.The ACS patients were divided into mild group(47 cases),moderate group(34 cases) and severe group(19 cases),according to the Gensini score.The serum levels of miR-146 a and miR-34 a in each group were detected by quantitative real-time polymerase chain reaction.Follow-up one year,the occurrence of major adverse cardiovascular events(MACE) were compared between two groups.Result:Compared with the control group,the serum levels of miR-146 a and miR-34 a in ACS group were significantly higher(P<0.05).The serum levels of miR-146 a and miR-34 a in the severe group were higher than moderate group or mild group(P<0.05),and the serum levels of miR-146 a and miR-34 a in the moderate group were higher than mild group(P<0.05).Follow-up one year,the serum levels of miR-146 a and miR-34 a in the MACE sub-group were higher than non-MACE sub-group(P<0.05).Conclusion:Serum levels of miR146 a and miR-34 a are high in patients with ACS,and are closely related to the severity of coronary artery disease.
- acute coronary syndrome /
- miR-146a /
- miR-34a /
- cocronary artery disease /
- major adverse cardiovascular events

HTML全文

参考文献(18)

[1]	秦小伟,项鹰羽,黄立娟.循环miRNA在急性冠脉综合征中的研究进展[J].国际免疫学杂志,2018,41(1):89-93.
[2]	Wang W,Li T,Gao L,et al.Diagnostic and prognostic impact of circulating microRNA-208b and microRNA-499 in patients with acute coronary syndrome[J].Biomark Med,2020,14(2):87-95.
[3]	Qiu H,Chen Z,Lv L,et al.Associations between microRNA polymorphisms and development of coronary artery disease:a case-control study[J].DNA Cell Biol,2020,39(1):25-36.
[4]	许佳昕,吕伟.急性ST段抬高型心肌梗死患者血清miR-1-3p、H-FABP检测水平及与冠状动脉病变程度的关系[J].临床急诊杂志,2018,19(12):816-820.
[5]	Gensini GG.A more meaningful scoring system for determining the severity of coronary heart disease[J].Am J Cardiol,1983,51(3):606.
[6]	Ahlin F,Arfvidsson J,Vargas KG,et al.MicroRNAs as circulating biomarkers in acute coronary syndromes:A review[J].Vascul Pharmacol,2016,81:15-21.
[7]	马智会,朱永武.冠状动脉血管内超声钙化特征联合血清miRNA-1、miRNA-208b对NSTE-ACS患者PCI术后冠状动脉再狭窄的预测价值[J].临床心血管病杂志,2019,35(9):795-800.
[8]	Bukauskas T,Mickus R,Cereskevicius D,et al.Value of Serum miR-23a,miR-30d,and miR-146a biomarkers in ST-elevation myocardial infarction[J].Med Sci Monit,2019,25:3925-3932.
[9]	Arroyo AB,de Los Reyes-García AM,Rivera-Caravaca JM,et al.MiR-146a regulates neutrophil extracellular trap formation that predicts adverse cardiovascular events in patients with atrial fibrillation[J].Arterioscler Thromb Vasc Biol,2018,38(4):892-902.
[10]	刘艳宾,杨树涵,陈红伟,等.老年冠心病患者血清miRNA-34a表达及其临床意义[J].实用医学杂志,2019,35(22):3482-3486.
[11]	Kaur A,Mackin ST,Schlosser K,et al.Systematic review of microRNA biomarkers in acute coronary syndrome and stable coronary artery disease[J].Cardiovasc Res,2020,116(6):1113-1124.
[12]	Wu S,Sun H,Sun B.MicroRNA-145 is involved in endothelial cell dysfunction and acts as a promising biomarker of acute coronary syndrome[J].Eur J Med Res,2020,25(1):2.
[13]	王木琼,孙向阳.美托诺尔对急性心肌梗死患者miRNA-423-5p与整合素连接激酶的影响[J].临床心血管病杂志,2019,35(10):899-902.
[14]	Bagavad Gita J,George AV,Pavithra N,et al.Dysregulation of miR-146a by periodontal pathogens:A risk for acute coronary syndrome[J].J Periodontol,2019,90(7):756-765.
[15]	Barraclough JY,Joan M,Joglekar MV,et al.MicroRNAs as prognostic markers in acute coronary syndrome patients-a systematic review[J].Cells,2019,8(12):1572.
[16]	Tong KL,Mahmood Zuhdi AS,Wan Ahmad WA,et al.Circulating MicroRNAs in young patients with acute coronary syndrome[J].Int J Mol Sci,2018,19(5):E1467.
[17]	Rocic P.Can microRNAs be biomarkers or targets for therapy of ischemic coronary artery disease in metabolic syndrome?[J].Curr Drug Targets,2017,18(15):1722-1732.
[18]	Moushi A,Michailidou K,Soteriou M,et al.MicroRNAs as possible biomarkers for screening of aortic aneurysms:a systematic review and validation study[J].Biomarkers,2018,23(3):253-264.